News &amp; Updates

Treatment with patritumab deruxtecan (HER3-DXd) confers survival benefits on patients with epidermal growth factor receptor (EGFR)-mutated nonsmall-cell lung cancer (NSCLC) following EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy, results of a phase I study have shown.

10 May 2024

Pembrolizumab offers survival benefits in early-stage TNBC

Neoadjuvant pembrolizumab plus chemotherapy improves event-free survival (EFS) in high-risk, early-stage triple-negative breast cancer (TNBC) patients with residual cancer burden (RCB), suggests a study.

10 May 2024

Proteome-based diagnostic test shows promise for early cancer detection

A novel proteome-based screening test showed potential for early detection of cancer in a study.

Short-term oxygen supplementation improves exercise capacity in fibrotic interstitial lung disease

For patients with fibrotic interstitial lung disease, undergoing oxygen therapy in the short term helps increase exercise duration and reduce fatigue and dyspnoea during exercise, as shown in a study.

Schools need to up their game on students’ mental health

The Chinese University of Hong Kong (CUHK)’s Healthy School Forum reveals alarming data on students’ mental health, which call for adoption of the WHO’s health-promoting school (HPS) framework in all schools in Hong Kong.

Solo ticagrelor after 1-month DAPT: Is it time to change practice?

Dropping aspirin for ticagrelor monotherapy 1 month after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) is as good as dual antiplatelet therapy (DAPT) in the ULTIMATE-DAPT* trial presented at ACC.24.

10 May 2024

Fatty acid may influence bipolar disorder risk

09 May 2024 by

Genetic predisposition to higher levels of arachidonic acid may play a causal role in bipolar disorder (BPD), as suggested in a Mendelian randomization study.

Albumin use, AKI predict respiratory failure in cirrhotic patients

Some hospitalized patients with cirrhosis who are not exposed to terlipressin develop respiratory failure (RF), reveals a study.

Vonoprazan-amoxicillin on par with quadruple therapy for H pylori eradication

09 May 2024 by

Dual therapy with vonoprazan and amoxicillin (VA-dual) for 10 days results in a 90.8-percent eradication rate of Helicobacter pylori (H pylori) and fewer adverse events (AEs) compared with the standard 14-day bismuth-based quadruple therapy (B-quadruple), a study has shown.

09 May 2024

High- vs low-risk T1a EAC tied to more extraesophageal metastases

Patients with high-risk T1a esophageal adenocarcinoma (EAC) undergoing successful endoscopic eradication therapy (EET) appear to have a greater rate of extraesophageal metastases than those with low-risk T1a EAC on long-term follow-up, reports a study.